Protocol Ledger

NCT05378945 · Phase III · COMPLETED

Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease

Interventional Phase III clinical trial protocol NCT05378945 sponsored by Corxel Pharmaceuticals in Ophthalmology and Sensory, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-07-22 Enrollment: 340 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05378945
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)340 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05378945
Protocol FieldVerified Registry Value
NCT IdentifierNCT05378945
Consolidated Lead SponsorCorxel Pharmaceuticals
Therapeutic Condition CohortOphthalmology and Sensory
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment340 participants (ACTUAL)
Registered Start Date2022-07-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Ophthalmology and Sensory Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI